Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study (vol 123, pg 1039, 2023)

被引：0
|
作者：
Guerzoni, Simona [1 ,2 ]
Baraldi, Carlo [3 ]
Brovia, Daria [1 ,2 ]
Cainazzo, Maria Michela [1 ,2 ]
Lo Castro, Flavia [4 ]
Pani, Luca [1 ,2 ,5 ,6 ,7 ]
机构：
[1] AOU Policlin Modena, Pharmacol & Clin Metab Toxicol Headache Ctr, Digital & Predict Med, Modena, Italy
[2] AOU Policlin Modena, Dept Specialist Med, Drug Abuse Lab Clin Pharmacol & Pharmacogen, Modena, Italy
[3] Univ Modena & Reggio Emilia, PhD Sch Neurosci, Dept Biomed Metab & Neural Sci, Modena, Italy
[4] Univ Modena & Reggio Emilia, Postgrad Sch Pharmacol, Dept Biomed Metab & Neural Sci, Modena, Italy
[5] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Pharmacol Unit, Modena, Italy
[6] Univ Miami, Dept Psychiat & Behav Sci, Miami, FL USA
[7] VeraSci, Durham, NC USA
来源：
ACTA NEUROLOGICA BELGICA | 2023年 / 123卷 / 05期
关键词：
D O I：
10.1007/s13760-023-02340-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：2075 / 2075
页数：1
相关论文
共 43 条
  • [1] Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
    Simona, Guerzoni
    Carlo, Baraldi
    Daria, Brovia
    Michela, Cainazzo Maria
    Flavia, Lo Castro
    Luca, Pani
    ACTA NEUROLOGICA BELGICA, 2023, 123 (03) : 1039 - 1047
  • [2] Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
    Simona Guerzoni
    Carlo Baraldi
    Daria Brovia
    Maria Michela Cainazzo
    Flavia Lo Castro
    Luca Pani
    Acta Neurologica Belgica, 2023, 123 : 1039 - 1047
  • [3] Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study
    Simona Guerzoni
    Carlo Baraldi
    Daria Brovia
    Maria Michela Cainazzo
    Flavia Lo Castro
    Luca Pani
    Acta Neurologica Belgica, 2023, 123 : 2075 - 2075
  • [4] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Simona Guerzoni
    Flavia Lo Castro
    Daria Brovia
    Carlo Baraldi
    Luca Pani
    Neurological Sciences, 2024, 45 : 1661 - 1668
  • [5] Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study
    Guerzoni, Simona
    Castro, Flavia Lo
    Brovia, Daria
    Baraldi, Carlo
    Pani, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1661 - 1668
  • [6] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 179 - 179
  • [7] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 120 - 121
  • [8] Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
    Caronna, Edoardo
    Jose Gallardo, Victor
    Alpuente, Alicia
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [9] Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
    Edoardo Caronna
    Victor José Gallardo
    Alicia Alpuente
    Marta Torres-Ferrus
    Patricia Pozo-Rosich
    The Journal of Headache and Pain, 2021, 22
  • [10] Long-term effectiveness of monoclonal anti-CGRP antibodies in patients with migraine in real life
    Perez Prol, C.
    Espinoza Vinces, C.
    Villino Rodriguez, R.
    Atorrasagasti Villar, A.
    Gimeno Rodriguez, M.
    Benitez Martinez, B.
    Beistegui Sarobe, M.
    Sanchez del Rio, M.
    Irimia Sieira, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
12345